BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35042311)

  • 1. Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.
    Teng QL; Yang XR; Wen S; Dai ZH; Wang HL; Liu TQ; Wang L; Fan B; Liu ZY
    Asian J Androl; 2022; 24(5):525-532. PubMed ID: 35042311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated macrophages and PD-L1 in prostate cancer: a possible key to unlocking immunotherapy efficacy.
    Wang J; Wu W; Yuan T; Wang L; Zang L; Liu Q; Wang L; Huo X; Huo B; Tang Y; Wang H; Zhao Z
    Aging (Albany NY); 2024 Jan; 16(1):445-465. PubMed ID: 38189834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
    Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
    Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2019 Sep; 98(38):e17257. PubMed ID: 31567999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Amemiya R; Miyoshi T; Aokage K; Suzuki J; Hoshino H; Udagawa H; Tane K; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Goto K; Ikeda N; Tsuboi M; Ishii G
    Lung Cancer; 2021 Mar; 153():56-65. PubMed ID: 33454518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
    Parra ER; Behrens C; Rodriguez-Canales J; Lin H; Mino B; Blando J; Zhang J; Gibbons DL; Heymach JV; Sepesi B; Swisher SG; Weissferdt A; Kalhor N; Izzo J; Kadara H; Moran C; Lee JJ; Wistuba II
    Clin Cancer Res; 2016 Dec; 22(24):6278-6289. PubMed ID: 27252415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
    Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
    Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
    Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features and prognostic significance of pulmonary adenocarcinoma with signet ring cell components: meta-analysis and SEER analysis.
    Tan Y; Huang YH; Xue JW; Zhang R; Liu R; Wang Y; Feng ZB
    Clin Exp Med; 2023 Dec; 23(8):4341-4354. PubMed ID: 37779169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between PD-1 / PD-L1 expression and clinicopathological features in sarcomatoid renal cell carcinoma.
    Zhao Y; Shi Z; Xie Y; Li N; Chen H; Jin M
    Asian J Surg; 2024 Jan; 47(1):163-168. PubMed ID: 37419794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
    Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
    Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.